In July 2019, Liryc signed a partnership contract with the Careline Solutions company, for the purpose of improving remote monitoring of patients suffering from chronic heart pathologies. With nearly 1,200 patients monitored by the company in France, Careline makes precious data available to research thanks to its unique innovative technology. 

Designed as a multi-mode remote monitoring tool, the Careline Solutions platform makes it possible to group together into a single point all of the biometric and biological data as well as that of pacemakers and implantable defibrillators, for a more complete daily follow-up. It is in this objective of optimizing the care that the partnership with Liryc lies, prospectively making use of the remote monitoring data in an ambitious artificial intelligence research program. 

Today, the yield from the reading of teletransmitted data from implantable cardiac prostheses is low as it is too voluminous. The first line of research of the teams therefore has for objective to develop an artificial intelligence algorithm that can read and sort this data autonomously, in order to facilitate the work of the remote monitoring teams. The preliminary results are already very promising. Introducing artificial intelligence into the platform also means developing a complex program that aims to predict the phenomena of ventricular tachycardia, ventricular fibrillation or severe heart decompensations that lead to death. 

The teams are also working on extending the platform to other pathologies such as the remote monitoring of congenital heart defects, diabetes or chronic obstructive pulmonary disease (COPD), pathologies that moreover represent a genuine financial challenge in terms of care. The current follow-up of chronic heart pathologies already alone makes it possible to prevent most hospitalizations. This is a major stake when there are 150,000 people hospitalized every year in France for heart failure. At the horizon of 2021, Liryc and Careline will renew their partnership agreement in order to continue the ambitious research program. It will also entail responding to the challenge of raising funds to continue optimizing the platform.